Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»HealthCare»Cofttek, China’s Largest Manufacturer of PEA, Draws Attention of Investors
    HealthCare

    Cofttek, China’s Largest Manufacturer of PEA, Draws Attention of Investors

    Marie JonesBy Marie JonesFebruary 14, 2021No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Cofttek Holding Limited, a Chinese pharmaceutical manufacturer, has recently drawn the attention of investors, following the U.S. introduction of the FDA drug ultramicronized Palmitoylethanolamide (PEA) for COVID-19 patients. Cofttek is China’s largest manufacturer of ultramicronized Palmitoylethanolamide (PEA) raw materials. Following the U.S. news, orders at Cofttek have surged, and production capacity has been saturated.

    Cofttek founder Dr. Zeng explained, “Following this FDA news, the share price of FSD Pharma (NASDAQ: HUGE), our main competitor in the USA, roared from $3 to $14 in a few days. As the largest PEA manufacturer in China, Cofttek has attracted similar attention from many investors in the industry.”

    About Palmitoylethanolamide (PEA): 

    Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent, one that is also found in foods such as eggs and milk, no serious side effects or drug-drug interactions have been identified.

    PEA is a naturally occurring fatty acid. It is similar to an endocannabinoid, which is one of a suite of molecules found in cannabis targeting CB2 receptors. CB2 receptors can modulate both inflammation and pain throughout the human body. COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm, which is not a virus killer. But Cofttek believes it can mitigate that immune response, which can be fatal.

    About Cofttek

    Cofttek Holding Limited, founded in 2008, is a high-tech pharmaceutical biochemical enterprise, integrating production, R&D and sales. It is located in Luohe Chemical Industry Park, in Luohe City, Henan Province, and is committed to the research and development of advanced pharmaceuticals, providing innovative products and high-quality services for the pharmaceutical industry.

    Media Contact:
    Dr. Zeng, Cofttek Holding Limited
    E: info@cofttek.com,T: 86 1390 2465871
    Website: https://www.cofttek.com

    Source: Cofttek Holding Limited

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleYutong Bus to serve FIFA Club World Cup Qatar 2020
    Next Article ALG Health Receives NIOSH Surgical Rating on Three Of Its American Made N95 Respirators

    Related Posts

    Avantor Expands RIM Single-Use Portfolio Across APAC

    September 17, 2026

    AGFA HealthCare Puts Clinical Attention at the Center of Enterprise Imaging at RSNA 2026

    September 14, 2026

    Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone

    September 9, 2026
    Add A Comment

    Comments are closed.

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.